Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.15 (market cap $6.57B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Repligen Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and Repligen Corporation Common Stock for 0 Days on average.
| IOVA | RGEN | |
|---|---|---|
Market Cap | $6.57B | $11.14B |
Volume | 11,838,721 | 1,259,263 |
Sector | Health | Health |
52-Week High | $14.82 | $194.57 |
52-Week Low | $1.81 | $102.87 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.50B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
